The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.00
Bid: 40.00
Ask: 42.00
Change: 0.00 (0.00%)
Spread: 2.00 (5.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 41.00
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

CamGraPhIC announces £1.26 million fundraising

5 Aug 2022 07:00

RNS Number : 9768U
Frontier IP Group plc
05 August 2022
 

Reach - a non-regulatory announcement

AIM: FIPP

05 August 2022

 

Frontier IP Group plc

("Frontier IP" or the "Group")

 

 

Portfolio news - CamGraPhIC announces former BT Group chair Sir Michael Rake to join board and £1.26 million fundraising

 

 

 

Frontier IP, a specialist in commercialising intellectual property, today announces that portfolio company CamGraPhIC (the "Company") has raised £1.26 million through an equity funding round from existing and new investors to develop and scale up its graphene-based photonics technology for use in high-speed data and telecommunications networks.

 

Sir Michael Rake, the former chair of BT Group plc, is an investor in CamGraPhIC and will be joining its board of directors by the end of the year. He is currently advising the Company on an informal basis.

 

The new funding is being raised through an advanced subscription agreement, meaning shares will be issued at a later date. Frontier IP's equity stake in the Company is 20.8 per cent. Frontier IP invested £300,000 and coordinated the funding round with investment platform Wealth Club. Its clients invested £813,475.

 

CamGraPhIC is developing graphene-based photonics technology for scalable, faster and cheaper optical transceivers, devices at the heart of high-speed data and telecommunications networks. They have the potential to become a core enabling technology for next generation 5G networks and beyond.

 

The transceivers are also more energy efficient, meaning they are not only cheaper to buy, but also to run. Other uses will include 6G mm wave, which has the potential to transmit data at speeds up to 1 terabyte per second, High Performance Computing and networks able to meet the demands of processor-intensive artificial intelligence applications.

 

Progress to date has been highly encouraging. Current versions of the technology have indicated speeds of up to 100Gbps per lane and operation across multiple wavebands. Their speed is about twice that achieved in laboratory conditions by equivalent technologies, while it is projected that they consume 70 per cent less energy.

 

Proceeds from the funding round will be used to complete fabrication and testing of the demonstration devices. The technology has attracted interest from major multinationals in the semiconductor and telecommunications sectors. Customer testing is expected to begin in September.

 

Sir Michael is Chair of Wireless Logic Group Ltd, Chair of Ola UK Pvt Ltd, Chair of Phoenix Global Resources plc, Majid Al Futtaim Holdings LLC, Newday Group UK Ltd and is also a Senior Advisor for Citi Group.

 

His previous roles, in addition to chairing BT Group, include Chair of Worldplay Group plc, EasyJet plc and President of the Confederation of British Industry. He was also a member of the Prime Minister's Business Advisory Group, Deputy Chair of Barclays plc, and a director of S&P Global Inc.

 

CamGraPhIC's underlying graphene-photonics technology has a host of further applications and is being developed under licence from the University of Cambridge.

Sir Michael Rake said: "As an investor and informal adviser to the Company, I have been very impressed with its technology and the possibilities that it opens up for transforming the vital infrastructure of data and telecommunications networks. It will be a pleasure to become more closely involved as a member of the board of directors, and I look forward to taking up the role later this year."

Paul Mantle, Chief Executive Officer, CamGraPhIC, said: "We are delighted to secure this funding and that Sir Michael is joining the CamGraPhIC board of directors. His experience in telecommunications and the wider business world will be invaluable as we grow.

"Our graphene-based photonics technology has the potential to transform high-speed data and telecommunications. We look forward to evaluating the technology with customers and receiving the first results."

Neil Crabb, Frontier IP Chief Executive Officer, said: "Sir Michael's decision to join the CamGraPhIC board of directors is a strong validation of the Company's technology. The world needs ever greater amounts of data, and we believe this technology could prove critical in meeting those demands."

Alex Davies, CEO and Founder of Wealth Club said: "As a significant existing shareholder in the Company (20.9 per cent), we were delighted to be able to support CamGraPhIC for the second time. Wealth Club clients invested £813,475 in this latest round, having previously invested £1.5m; giving the business the best opportunity to ramp up progress in a race to become the first to launch this exciting technology to market. The Company has a compelling mix of stakeholders - strong academics, strategic investors and management with close links to major industrial partners."

 

ENQUIRIES

 

 

Frontier IP Group Plc

T: 020 7332 2338

Neil Crabb, Chief Executive Officer

Andrew Johnson, Communications and investor relations

andrew.johnson@frontierip.co.uk

Company website: www.frontierip.co.uk

neil@frontierip.co.uk

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser)

Nick Athanas / George Payne

 

 

 

 

T: 0203 328 5656

 

 

 

 

 

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

About Reach announcements

 

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRASSFFELEESEFA
Date   Source Headline
2nd May 20247:00 amRNSFrontier IP announces stake in DiaGen
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
11th Sep 20237:00 amRNSPortfolio news – Pulsiv appoints Chairman and CPO
8th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
10th Aug 20238:45 amRNSPortfolio news – Fieldwork Robotics
24th Jul 20237:00 amRNSPortfolio news – CamGraPhIC loan facility
20th Jul 20235:18 pmRNSHolding(s) in Company
1st Jun 20237:00 amRNSSale of shares in Exscientia
26th May 20236:06 pmRNSHolding(s) in Company
9th May 20237:00 amRNSTopps Tiles launches first Alusid made tile range
21st Apr 20234:00 pmRNSDirectorate Change
20th Apr 20235:26 pmRNSHolding(s) in Company
27th Mar 20235:17 pmRNSHolding(s) in Company
17th Mar 20232:46 pmRNSGrant of options
15th Mar 20237:00 amRNSBoard changes
15th Mar 20237:00 amRNSUnaudited Half Year Results
30th Jan 20237:00 amRNSAlusid in collaboration with Imerys
9th Jan 20237:00 amRNSCelerum appoints David Gladding as CEO
9th Dec 20224:08 pmRNSResult of AGM
7th Dec 20221:25 pmEQSThe Vaccine Group completes two deadly disease vaccination projects
6th Dec 20227:00 amRNSFrontier IP to host Portfolio Demo Day
5th Dec 20227:00 amRNSThe Vaccine Group completes Lassa fever project
2nd Dec 20227:00 amRNSThe Vaccine Group completes vaccine project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.